Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukine-2 to standard ipilimumab treatment in metastatic melanoma

M. W. Rohaan; T. H. Borch; J. H. van den Berg; M. H. Geukes Foppen; M. Donia; Met; B. Nuijen; M. van Zon; E. A. M. Bakker; R. de Boer; L. M. Pronk; S. Wilgenhof; C. U. Blank; J. V. van Thienen; A. C. J. van Akkooi; I. M. Svane; J. B. A. G. Haanen

doi:10.1093/annonc/mdy289.059

Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukine-2 to standard ipilimumab treatment in metastatic melanoma

M. W. Rohaan
, T. H. Borch
, J. H. van den Berg
, M. H. Geukes Foppen
, M. Donia
, Met
, B. Nuijen
, M. van Zon
, E. A. M. Bakker
, R. de Boer
, L. M. Pronk
, S. Wilgenhof
, C. U. Blank
, J. V. van Thienen
, A. C. J. van Akkooi
, I. M. Svane
, J. B. A. G. Haanen

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	viii465
Journal	Annals of oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy289.059
Publication status	Published - 1 Oct 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1093/annonc/mdy289.059

Cite this

Rohaan, M. W., Borch, T. H., van den Berg, J. H., Geukes Foppen, M. H., Donia, M., Met, Nuijen, B., van Zon, M., Bakker, E. A. M., de Boer, R., Pronk, L. M., Wilgenhof, S., Blank, C. U., van Thienen, J. V., van Akkooi, A. C. J., Svane, I. M., & Haanen, J. B. A. G. (2018). Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukine-2 to standard ipilimumab treatment in metastatic melanoma. Annals of oncology, 29, viii465. https://doi.org/10.1093/annonc/mdy289.059

@article{4974008e7b41473b9cdf418d89e05263,

title = "Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukine-2 to standard ipilimumab treatment in metastatic melanoma",

author = "Rohaan, \{M. W.\} and Borch, \{T. H.\} and \{van den Berg\}, \{J. H.\} and \{Geukes Foppen\}, \{M. H.\} and M. Donia and Met and B. Nuijen and \{van Zon\}, M. and Bakker, \{E. A. M.\} and \{de Boer\}, R. and Pronk, \{L. M.\} and S. Wilgenhof and Blank, \{C. U.\} and \{van Thienen\}, \{J. V.\} and \{van Akkooi\}, \{A. C. J.\} and Svane, \{I. M.\} and Haanen, \{J. B. A. G.\}",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy289.059",

language = "English",

volume = "29",

pages = "viii465",

journal = "Annals of oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

Rohaan, MW, Borch, TH, van den Berg, JH, Geukes Foppen, MH, Donia, M, Met, Nuijen, B, van Zon, M, Bakker, EAM, de Boer, R, Pronk, LM, Wilgenhof, S, Blank, CU, van Thienen, JV, van Akkooi, ACJ, Svane, IM & Haanen, JBAG 2018, 'Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukine-2 to standard ipilimumab treatment in metastatic melanoma', Annals of oncology, vol. 29, pp. viii465. https://doi.org/10.1093/annonc/mdy289.059

Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukine-2 to standard ipilimumab treatment in metastatic melanoma. / Rohaan, M. W.; Borch, T. H.; van den Berg, J. H. et al.
In: Annals of oncology, Vol. 29, 01.10.2018, p. viii465.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukine-2 to standard ipilimumab treatment in metastatic melanoma

AU - Rohaan, M. W.

AU - Borch, T. H.

AU - van den Berg, J. H.

AU - Geukes Foppen, M. H.

AU - Donia, M.

AU - Met, null

AU - Nuijen, B.

AU - van Zon, M.

AU - Bakker, E. A. M.

AU - de Boer, R.

AU - Pronk, L. M.

AU - Wilgenhof, S.

AU - Blank, C. U.

AU - van Thienen, J. V.

AU - van Akkooi, A. C. J.

AU - Svane, I. M.

AU - Haanen, J. B. A. G.

PY - 2018/10/1

Y1 - 2018/10/1

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85081530353&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/32137194

U2 - 10.1093/annonc/mdy289.059

DO - 10.1093/annonc/mdy289.059

M3 - Article

C2 - 32137194

SN - 0923-7534

VL - 29

SP - viii465

JO - Annals of oncology

JF - Annals of oncology

ER -

Rohaan MW, Borch TH, van den Berg JH, Geukes Foppen MH, Donia M, Met et al. Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukine-2 to standard ipilimumab treatment in metastatic melanoma. Annals of oncology. 2018 Oct 1;29:viii465. doi: 10.1093/annonc/mdy289.059

Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukine-2 to standard ipilimumab treatment in metastatic melanoma

UN SDGs

Access to Document

Other files and links

Cite this